Medico Remedies (BOM:540937) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540937 Medico Remedies Ltd BOM:540937
86 GF Score
Price ₹35.48
GF Value ₹79.80
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medico Remedies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medico Remedies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Medico Remedies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Medico Remedies's annualized EBITDA for the quarter that ended in Jun. 2026 was ₹179 Mil. Medico Remedies's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medico Remedies's Debt-to-EBITDA or its related term are showing as below:

BOM:540937' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.54   Med: 1.78   Max: 5.05
Current: 0.81

During the past 13 years, the highest Debt-to-EBITDA Ratio of Medico Remedies was 5.05. The lowest was 0.54. And the median was 1.78.

BOM:540937's Debt-to-EBITDA is ranked better than
64.75% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs BOM:540937: 0.81

Medico Remedies  (BOM:540937) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medico Remedies Debt-to-EBITDA Related Terms


Medico Remedies Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Medico Remedies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medico Remedies Debt-to-EBITDA Chart

Medico Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.35 0.72 0.54 0.83 0.84

Medico Remedies Quarterly Data
Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.65 N/A 0.84 N/A

BOM:540937 vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medico Remedies Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medico Remedies's Debt-to-EBITDA falls into.


BOM:540937
86GF Score
Medico Remedies Ltd BOM:540937
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medico Remedies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medico Remedies's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(189.909 + 2.863) / 229.605
=0.84

Medico Remedies's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + 0) / 178.764
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Medico Remedies (BOM:540937) Overvalued in 2026?

Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued. The current stock price of ₹35.48 is trading 55.5% below its estimated GF Value™ of ₹79.80. GuruFocus considers Medico Remedies to be Significantly Undervalued.

Key valuation signals for BOM:540937:

  • Debt-to-EBITDA: N/A
  • GF Value™: ₹79.80 vs. price of ₹35.48 (55.5% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the BOM:540937 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medico Remedies Business Description

Other Exchanges MEDICO:India
Address N. S. Phadke Marg, Opposite Teligali, 1105/1106, 11th Floor, Hubtown Solaris, Andheri (East), Mumbai, MH, IND, 400069
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
86GF Score

Get the complete analysis for BOM:540937

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹35.48
Price
₹79.80
GF Value